One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...

A year ago, applications for a cell-cultured foie gras product were dropped off at the United States Food and Drug ...

Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he's pulling the plug on nearly $500 million in ...

Q2 2025 Management View CEO Adam S. Grossman opened by stating that "ADMA's second quarter 2025 performance underscores the strength of our operating model, the success of our strategic execution and ...

As of fiscal year-end 2025, McKesson held cash and cash equivalents of $5.7 billion with outstanding debt at $4.4 billion. Roughly one third of its debt is due to mature over the next three years, and ...

Oral ciprofloxacin alone was as effective as a regimen combined with an injectable antibiotic for bubonic plague, a ...

Discover Delcath Systems' Q2 2025 performance: 20% revenue growth, profitability boost, and 175% projected HEPZATO volume increase.

A federal SNAp waiver was recently approved by the U.S. Department of Agriculture to remove sugary beverages from the ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...